Premium
IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO‐RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END‐POINT OF THE I LOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK.
Author(s) -
Soussain C.,
Choquet S.,
Houillier C.,
Bijou F.,
Houot R.,
Boyle E.,
Gressin R.,
NicolasVirelizier E.,
Barrie M.,
MoluçonChabrot C.,
Lelez M.,
Clavert A.,
Coisy S.,
Bretonnière M. Ertault,
El Yamani A.,
Touitou V.,
Cassoux N.,
Boussetta S.,
Broussais F.,
GelasDore B.,
Barzic N.,
Ghesquières H.,
HoangXuan K.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_59
Subject(s) - ibrutinib , medicine , clinical endpoint , oncology , diffuse large b cell lymphoma , primary central nervous system lymphoma , refractory (planetary science) , interim analysis , rituximab , phases of clinical research , progressive disease , lymphoma , gastroenterology , clinical trial , chemotherapy , leukemia , chronic lymphocytic leukemia , biology , astrobiology